(PQA3) Why is Ovarian Cancer Primarily a Disease of Postmenopausal Women
(PQA3) 为什么卵巢癌主要是绝经后妇女的疾病
基本信息
- 批准号:9062409
- 负责人:
- 金额:$ 19.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAgeAgingAreaAtrophicCancer DetectionCancer EtiologyCell AgingCellsChemotaxisCicatrixCollagenCollagen FiberColorCorpora AlbicantiaDevelopmentDiagnosisDiagnostic Neoplasm StagingDiseaseEarly DiagnosisEnzymesEpidemiologyEpithelialEpithelial CellsEpithelial cystEpithelial ovarian cancerEventExposure toExtracellular MatrixFertilizationFiberFibroblastsFibrosisGenesGrowthHealthHormonal ChangeHormonesHumanImageImageryImmuneImmunityImplantIncidenceInfiltrationInflammationInterventionLaboratoriesLeadLeftLesionLifeLoose connective tissueMalignant Epithelial CellMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMammary NeoplasmsMammographic DensityMenopausal StatusMenopauseMolecularMyofibroblastNeoplasm MetastasisOvarianOvarian FollicleOvarian Serous AdenocarcinomaOvaryOvulationPathogenesisPhagocytesPhasePlayPostmenopausePremature MenopausePremenopausePreventionPreventive InterventionProcessProductionReactive Oxygen SpeciesReproductive PeriodsResearchRiskRoleScreening for Ovarian CancerSeed ImplantationSeedsShapesSignaling MoleculeSoilSpecimenStagingStructureSurfaceSurvival RateTestingTissuesTransgenic MiceTrichrome stainTubeWomanbasecalcificationcancer cellcancer initiationcancer preventioncancer riskcancer typeclinical practicecorpus luteumcrosslinkepidemiologic datafimbriagenetic signatureimplantationimpressioninsightmacrophagemalignant breast neoplasmmouse modelneoplasticneoplastic cellovarian cancer preventionreproductivetheoriestumortumor microenvironmenttumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Epithelial ovarian cancer is predominantly a disease of postmenopausal women, with 80-90% of ovarian cancer cases occurring after the age of 40. The peak incidence of menopause occurs at age 51, while the peak incidence of invasive epithelial ovarian cancer occurs at age 63. Many theories of postmenopausal onset of ovarian cancer have been proposed, including incessant ovulation and inflammation, hormonal changes, reduced immunity, increased cell senescence and uncontrolled production of reactive oxygen species. A poor understanding of the initiating events in ovarian cancer has significantly hampered our efforts towards early ovarian cancer detection and prevention. It is increasingly accepted that ovarian cancer actually originates in the fallopian tube with malignant cells shedding to the adjacent ovary. Since the bulk of the tumor typically forms in the ovary, rather than the fallopian tube, ovaries must play a significant role in the early stages of cancer development. Epidemiologic data consistently show that ovarian cancer risk increases with the number of ovulatory cycles, indicating that ovulation plays a role in ovarian cancer etiology. However, it is paradoxical that women typically develop ovarian cancer more than a decade after their last ovulation. During the postmenopausal years, the ovarian follicles are depleted and much of the remaining ovary is remodeled to form fibrotic scar tissue. In contrast to the current view of the atrophic ovary as a nonfunctional fibrotic scar, we postulate that the collagen-rich microenvironment of the postmenopausal ovary provides fertile soil for the seeding of neoplastic tubal cells. This hypothesis is based on the recognized role of fibrosis and collagen
remodeling in facilitating tumorigenesis in several cancer types and on our recent finding that similar sets of collagen- remodeling genes are enriched during ovarian cancer progression and ovarian follicle regression. To test our hypothesis, we will first identify which molecular events are associated with human ovarian aging and menopausal status (Aim 1) and then test in a mouse model whether ovarian aging and/or fibrosis contribute to increased implantation of tubal cells into the ovary (Aim 2). Proof of our hypothesis will re-shape the current paradigms about ovarian cancer etiology. Moreover, determining which cellular and molecular processes promote and inhibit implantation of cancer cells into the ovary will provide needed insight into the identiy of targets for prevention and early detection.
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.
卵巢癌中的次优细胞减灭与基质活化增加的分子途径特征相关。
- DOI:10.1016/j.ygyno.2015.08.026
- 发表时间:2015-12
- 期刊:
- 影响因子:4.7
- 作者:Liu Z;Beach JA;Agadjanian H;Jia D;Aspuria PJ;Karlan BY;Orsulic S
- 通讯作者:Orsulic S
Title Sphingosine kinase 1 is required for TGF-beta mediated fibroblast-to-myofibroblast differentiation in ovarian cancer
标题 鞘氨醇激酶 1 是 TGF-β 介导的卵巢癌成纤维细胞向肌成纤维细胞分化所必需的
- DOI:
- 发表时间:2024-09-14
- 期刊:
- 影响因子:0
- 作者:Jessica A. Beach;P. Aspuria;Dong;K. Lawrenson;Hasmik Agadjanian;C. Walsh;B. Karlan;S. Orsulic
- 通讯作者:S. Orsulic
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANDRA ORSULIC其他文献
SANDRA ORSULIC的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANDRA ORSULIC', 18)}}的其他基金
BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance
BCCMA:克服卵巢癌的化疗耐药性:铂类耐药的生物标志物和靶向驱动因素的识别和验证
- 批准号:
10585641 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
癌症相关成纤维细胞改变实体恶性肿瘤中 B 细胞的组成
- 批准号:
10213442 - 财政年份:2020
- 资助金额:
$ 19.03万 - 项目类别:
Molecular characterization of ovarian cancer in a mouse model
小鼠模型卵巢癌的分子特征
- 批准号:
7214752 - 财政年份:2004
- 资助金额:
$ 19.03万 - 项目类别:
characterization of ovarian cancer in a mouse model
小鼠模型卵巢癌的特征
- 批准号:
6890993 - 财政年份:2004
- 资助金额:
$ 19.03万 - 项目类别:
characterization of ovarian cancer in a mouse model
小鼠模型卵巢癌的特征
- 批准号:
6704553 - 财政年份:2004
- 资助金额:
$ 19.03万 - 项目类别:
characterization of ovarian cancer in a mouse model
小鼠模型卵巢癌的特征
- 批准号:
7691494 - 财政年份:2004
- 资助金额:
$ 19.03万 - 项目类别:
相似国自然基金
巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
- 批准号:82304503
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α7nAChR激动剂通过PGC-1α和HO-1调控肾小管上皮细胞线粒体的质和量进而改善脓毒症急性肾损伤的机制研究
- 批准号:82372172
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
- 批准号:82374256
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
- 批准号:82300771
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
- 批准号:82374209
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
An immunotherapeutic IgY formulation against norovirus diarrhea
一种针对诺如病毒腹泻的免疫治疗 IgY 制剂
- 批准号:
10693530 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Sensitivity to Cannabis Effects and Cue Reactivity as Markers of a Developing Disorder in Adolescents
对大麻效应的敏感性和提示反应性作为青少年发育障碍的标志
- 批准号:
10586397 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
NS-PEACE Neonatal Seizures -Predicting Epilepsy and Assessing Comparative Effectiveness.
NS-PEACE 新生儿癫痫发作 - 预测癫痫并评估比较有效性。
- 批准号:
10568397 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
A mobile health framework for left ventricular end diastolic pressure diagnostics and monitoring.
用于左心室舒张末压诊断和监测的移动健康框架。
- 批准号:
10601929 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别:
Understanding CNS Stimulant Use and Safety in Veterans with TBI
了解患有 TBI 的退伍军人的中枢神经系统兴奋剂使用和安全性
- 批准号:
10538168 - 财政年份:2023
- 资助金额:
$ 19.03万 - 项目类别: